Start-up Mnemosyne's Series A Raises $5.4M for CNS Platform
By Marie Powers
Thursday, February 16, 2012
Mnemosyne Pharmaceuticals Inc., an emerging biotech targeting central nervous system (CNS) disorders, raised $5.4 million in a Series A financing to advance its work on a class of molecules known as subunit selective NMDA receptor modulators (SNRMs).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.